romidepsin for injection
For intravenous infusion only Initial US Approval: 2009

ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for: • Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

Facts about Romidepsin Injection

Approval Date: 2009
Proprietary Name: On Request
Active Ingredient(s):  Romidepsin Injection
Dosage Forms And Strengths: Injection, 10 mg, supplied with one Diluent vial containing 2 mL (deliverable volume) of solution
Company: Gloucester Pharmaceuticals, Inc
Current indications: cutaneous T-cell lymphoma (CTCL)
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Romidepsin Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Velexbru Tablet 80mg,
a Bruton’s Tyrosine Kinase Inhibitor in Japan

Velexbru® Tablet 80mg, a BTK Inhibitor, for Additional Indication of  Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma. Velexbru (tirabrutinib hydrochloride) is a medication used for the treatment of recurrent or refractory primary central nervous system lymphoma.

Facts about tirabrutinib-tablets

Disease Indications-Lymphoma
Manufacturer-Ono Pharmaceutical Co., Ltd.
Usage-Oral
Medicine Approved By-Pharmaceuticals and Medical Devices Agency (PMDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “tirabrutinib-tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

zanubrutinib capsules
for oral use Initial U.S. Approval: 2019

Brukinsa (zanubrutinib) is a Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL), Waldenström’s Macroglobulinemia (WM), relapsed/refractory Marginal Zone Lymphoma (MZL).

Facts about zanubrutinib capsules

Disease Indications-Lymphoma
Dosage Forms & Strengths Capsules: 80 mg
Manufacturer-BeiGene
Usage-Oral
Medicine Approved By:- European Medical Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “zanubrutinib capsules” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.